RAPP Stock — Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. (RAPP)

Updated October 16, 2026.

RAPP is a Stock. Total return is 32.5% over the past 2.4 years, 14.7 points behind SPY at 47.2%.

Rapport Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medicines for central nervous system disorders, with lead candidate RAP-219 in development for focal epilepsy and other conditions, alongside programs targeting chronic pain, migraine, and hearing disorders. The company does not currently distribute to shareholders. This security appeals to investors with a high risk tolerance seeking exposure to early-stage drug development in neurology and pain management.

RAPP performance versus SPY

Price and return data through 2026-10-16.

Total return is 32.5% over the past 2.4 years, 14.7 points behind SPY at 47.2%. Over the past year its total return — price change plus distributions reinvested — is 10.9%. Its deepest 1-year drawdown was 47.5%.

RAPP key facts

Asset type

Stock

Asset class

Equity

Inception date

06/07/2024

Distribution frequency

None

Last close

$27.57 (as of 2026-10-16)

Market cap

$1,322,761,345

Average volume

412062.0

Beta

1.219

Payout ratio

0.0%

EPS

$-2.91

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RAPP risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 47.5%.

Who may consider RAPP — and who may not

It is a weaker fit for investors who need monthly cash flow (RAPP does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on RAPP

• All tickers starting with R

Tagged: Healthcare.

Frequently asked questions